Biology Studies of Hematologic Cancers

Launched by NATIONAL CANCER INSTITUTE (NCI) · Jun 17, 2009

Keywords

ClinConnect Summary

Background:

Laboratory-based investigations have contributed to an improved understanding of pathophysiology and to the development of new therapies for hematologic malignancies.

The aim of this protocol is to facilitate biologic study of leukemias, pre-malignant conditions, myelodysplastic syndromes, lymphomas, and other blood disorders.

This is a sample acquisition protocol for targeted study of hematologic malignancies by a collaborative network of NIH investigators from multiple Institutes/Centers.

Objective:

This biology protocol is designed to allow sample acquisition for use in ...

Gender

ALL

Eligibility criteria

• • INCLUSION CRITERIA
• Confirmed pathological diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not restricted to the following:
• • Acute Lymphocytic Leukemia (ALL)
• • Acute Myelogenous Leukemia (AML)
• • Myelodysplastic Syndrome (MDS)
• • Chronic Myelogenous Leukemia (CML)
• • Juvenile Myelomonocytic Leukemia (JMML, J-CML)
• • Non-Hodgkin's Lymphoma (NHL)
• • Hodgkin's Disease
• • Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care.
• • Age: \>= 1 and \<= 75 years.
• • Prior therapy: no restrictions
• • Subject, parent/guardian, legally authorized representative (LAR), or durable power of attorney must be able to give informed consent and sign the informed consent document.
• • EXCLUSION CRITERIA
• • None